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PURPOSE: Cardiopulmonary bypass is known to alter propofol pharmacokinetics in patients undergoing cardiac surgery. However, 
few studies have evaluated the impact of these alterations on postoperative pharmacodynamics. This study was designed to test the 
hypothesis that changes in propofol pharmacokinetics increase hypnotic effects after cardiopulmonary bypass. 
METHODS: Twenty patients scheduled for on-pump coronary artery bypass graft (group, n=10) or off-pump coronary artery 
bypass graft (group, n=10) coronary artery bypass grafts were anesthetized with sufentanil and a propofol target controlled infu-
sion (2.0 µg/mL). Depth of hypnosis was monitored using the bispectral index. Blood samples were collected from the induction 
of anesthesia up to 12 hours after the end of propofol infusion, at predetermined intervals. Plasma propofol concentrations were 
measured using high-performance liquid chromatography, followed by a non-compartmental propofol pharmacokinetic analysis. 
Data were analyzed using ANOVA, considering p<0.05 as significant.
RESULTS: After cardiopulmonary bypass, despite similar plasma propofol concentrations in both groups, bispectral index values 
were lower in the on-pump coronary artery bypass graft group. Time to extubation after the end of propofol infusion was greater 
in the on-pump coronary artery bypass graft group (334 ± 117 vs. 216 ± 85 min, p = 0.04). Patients undergoing cardiopulmonary 
bypass had shorter biological (1.82 ± 0.5 vs. 3.67 ± 1.15h, p < 0.01) and terminal elimination (6.27 ± 1.29 vs. 10.5h ± 2.18, p < 
0.01) half-life values, as well as higher total plasma clearance (28.36 ± 11.40 vs.18.29 ± 7.67 mL/kg/min, p = 0.03), compared to 
patients in the off-pump coronary artery bypass graft group.
CONCLUSION: Aside from the increased sensitivity of the brain to anesthetics after cardiopulmonary bypass, changes in propofol 
pharmacokinetics may contribute to its central nervous system effects. 
KEYWORDS: Propofol; Target controlled infusion; Pharmacokinetics; Pharmacodynamics; Coronary surgery; Cardiopulmonary 
bypass.
INTRODUCTION
Continuous infusion of propofol using a target-
controlled infusion system (TCI)1 facilitates rapid arousal 
and early tracheal extubation after cardiac surgery,2 which 
may contribute to reduced postoperative mechanical 
ventilation time, shortened length of stay in the intensive 
care unit and lower hospital costs. On the other hand, use of 
cardiopulmonary bypass (CPB) during cardiac surgery has 
been shown to alter the plasma drug concentration,3,4 drug-
protein binding,5 and brain sensitivity to some anesthetics,6 
resulting in increased residual postoperative hypnosis and an 
extended duration of mechanical ventilation. Hemodilution, 
hypothermia, reduction in hepatic blood, and impairment of 
hepatic high-extraction drug clearance7 have been proposed 
as mechanisms that may underlie CPB alterations of drug 
pharmacokinetics (PK) and pharmacodynamics (PD). 216
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CPB-induced alterations in propofol PK have been 
described in patients undergoing cardiac surgery.8-12 Hiraoka 
et al. found that the fraction of unbound propofol in blood 
increased by two-fold during cardiopulmonary bypass.8 
Hammaren et al. observed that, during CPB, the unbound 
propofol concentration did not change, but auditory evoked 
potential latency was prolonged compared with baseline 
values measured after the induction of anesthesia and before 
the start of CPB.12 Takizawa et al. reported that the anesthetic 
effect of propofol significantly increased during CPB, 
without any alteration in the total drug concentration.5 
While CPB-induced propofol PK alterations have 
been the subject of several studies, there have been no 
investigations comparing CPB-induced alterations in 
propofol PK-PD to a control group of patients undergoing 
cardiac surgery without CPB. This study was designed to test 
the hypothesis that changes in the PK of propofol increase 
its hypnotic effects after CPB, as evaluated by changes in 
bispectral index (BIS) values.
METHODS
The study protocol was approved by the Hospital 
Committee at the University of São Paulo and is in 
accordance with the Helsinki Declaration; written informed 
consent was obtained from each patient. Twenty patients 
aged between 52-75 years with left ventricular ejection 
fractions > 50% and normal hepatic function who were 
scheduled for elective coronary artery surgery were selected 
for this study. The patients were assigned to either the on-
pump coronary artery bypass graft (CABG n=10) or off-
pump coronary artery bypass (OPCAB n=10) surgery group 
based on the anatomical characteristics of the coronary 
arteries. A single surgical team operated on all patients.
Pre-anesthetic medication consisted of midazolam 
0.2 mg/kg administered orally 30 min before surgery, 
with a maximum dose of 15 mg. After cardiovascular 
monitoring, a specific intravenous line was inserted in 
the right arm for propofol infusion. General anesthesia 
was induced using sufentanil (0.5 µg/kg), pancuronium 
(0.1 mg/kg) and propofol TCI (DiprivanR, Astra-Zeneca, 
Rueil-Malmaison, France) to achieve a predicted plasma 
concentration of 2.0 µg/mL in 30 seconds through a propofol 
infusion device (DiprifusorR, Astra-Zeneca, Detroit, USA), 
according to Marsh’s pharmacokinetic model13. Anesthesia 
was maintained by continuous infusion of sufentanil   
(0.5 µg.kg-1.h-1) and propofol TCI to maintain a predicted 
plasma concentration of 2 µg/mL. 
After tracheal intubation, mechanical ventilation was 
initiated using a Cicero ventilator (Drägger, Lubeck, 
Germany) with a tidal volume of 8 mL/kg, respiratory 
frequency of 12 breaths per minute, I:E ratio of 1:2, inspired 
oxygen fraction of 0.6 and 5 cm H2O PEEP. Patients in the 
OPCAB group received an intravenous dose of heparin, 100 
UI/kg, before the beginning of anastomosis, and the CABG 
group received 400 UI/kg of heparin before the initiation of 
CPB. After initiation of CPB using a centrifugal pump and 
a membrane oxygenator primed with 1500 mL of Lactated 
Ringer Solution and 250 mL of mannitol 20%, patients were 
cooled to a core temperature of 32-34ºC. This temperature 
was maintained until the end of the grafting procedure. Upon 
rewarming to 37ºC, the patients were weaned from CPB. 
Vasoactive drugs were infused to manage hemodynamic 
instability when judged necessary by the attending 
anesthesiologist.
Brain activity was continuously monitored by use of the 
BIS monitor (BISR XP, Aspect Medical Systems, Natick, 
MA) from admission to the operating room until 12 h after 
tracheal extubation. BIS values were collected as an average 
of recordings taken over a 60 s interval when each arterial 
blood sample was obtained for determination of the plasma 
propofol concentration.
The predicted plasma propofol concentration of 2 µg/mL 
was maintained throughout surgery, using the TCI delivery 
system and monitoring of blood samples (3 mL) that were 
drawn from the arterial catheter at 0, 5, 15, 30, 60, 120 and 
240 min intervals after the induction of anesthesia. In the 
CABG group, additional blood samples were collected 
immediately prior to the initiation of CPB and at 5, 15, 30 
and 60 min after the initiation of bypass, as well as upon 
discontinuation of CPB. At the end of surgery, the propofol 
TCI was reduced from 2 µg/mL to 1 µg/mL; samples were 
collected at 0, 5, 15, 30, 60, 120 and 240 min after onset. 
When tracheal extubation was clinically indicated, the 
propofol TCI was discontinued, and blood samples were 
subsequently collected at 0, 5, 15, 30, 60, 120, 240, 480 and 
720 min. All blood samples were drawn into glass tubes 
containing sodium EDTA.
The criteria for tracheal extubation were: 1) hemodynamic 
stability (i.e., normal arterial pressure, central venous 
saturation > 70 %, heart rate <120/min, no signs of myocardial 
ischemia); 2) adequate pulmonary function (i.e., PaO2 >80 
mm Hg and PaCO2 < 45 mm Hg at FiO2 0.4, spontaneous 
respiratory rate <30/min and tidal volume >5 mL/kg, PEEP 
= 5 cm H2O); 3) good muscle strength (i.e., spontaneous 
ventilation, ability to lift head); 4) consciousness (i.e., ability 
to follow simple commands) and 5) absence of surgical 
complications (i.e., bleeding <100 mL within previous 30 
minutes). Following extubation, patients were provided with 
an intravenous patient-controlled analgesia (PCA) system and 
were able to self-administer 1 mg bolus doses of morphine, as 
needed. All patients received supplemental oxygen via a face 217
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mask (flow between 3 and 10 L.min-1) following extubation 
to maintain oxygen saturation > 95%.
Pharmacokinetic analysis
For measurement of plasma propofol concentrations, 
blood samples were centrifuged at 3000 rpm for 30 min; 
the plasma was separated and stored in a freezer at -20oC. 
The plasma samples containing propofol were analyzed by 
high-performance liquid chromatography14,15. Validation of 
the analytical method demonstrated propofol detection and 
quantification limits of 0.05 and 0.10 mg/L, respectively. 
Intra- and inter-day precision were 8 and 9%, respectively, and 
intra- and inter-day accuracy were 92 and 93%, respectively. 
Pharmacokinetic parameters were calculated in the 
post-CPB period using the plasma drug concentration 
measured during the 12 hr observation period after stopping 
the propofol infusion, using PK-Solutions 2.0 non-
compartmental pharmacokinetics data analysis software 
(Ashland, OH). The groups were compared with respect 
to: distribution rate hybrid constant (α), distribution half-
life (T1/2α), fast elimination rate constant (β), biological 
half-life (T1/2ß), slow elimination rate constant (γ), terminal 
elimination half-life (T1/2 γ), total plasma clearance 
(CLT), volume of distribution beta (Vd β) and volume 
of distribution gamma (Vd γ). Since the interval from 
the beginning of surgery to tracheal extubation differed 
among patients, the software estimated plasma propofol 
concentrations for specific time points in order to permit 
inter-patient comparisons. 
Postoperative bispectral index values were plotted against 
simultaneous plasma propofol concentration measurements 
and PK-PD modeling was applied to both groups using 
GraphPad Prism for Windows v.3.0 software (GraphPad 
Software Inc., San Diego, CA). A sigmoid EMAX model 
was chosen to represent the hypnotic effect of propofol 
(i.e., BIS values) as a function of the measured plasma 
concentration. This PK-PD model is represented by the 
following equation:
Where “X” is the concentration of propofol and “Y” 
is the response. “Y” starts at the top (E0, the BIS value at 
baseline) and goes to the bottom (EMAX, the minimum BIS 
noted was considered to be the maximum effect), with a 
sigmoid shape. The EMAX, EC50 (concentration of drug 
required to produce 50% of maximum drug effect) and h (hill 
slope) parameters were compared among the investigated 
patient groups. To evaluate the adaptability of the model, the 
correlation index “R²” was applied. 
Normal distribution of data was tested using the 
Kolmogorov-Smirnov test. Demographic and surgical data 
were compared by means of the unpaired Student’s t-test or 
chi square test, as appropriate. We compared the doses of 
propofol infused during surgery, the amount infused from the 
end of surgery to the discontinuation of the propofol infusion 
immediately prior to tracheal extubation, and the time from 
the end of propofol infusion until the tracheal extubation 
between groups by means of the unpaired Student’s t-test. 
Measured plasma propofol concentrations and bispectral 
index values for the two groups were compared using 
analysis of variance for repeated measures followed by 
Wald or Student-Neumann-Keuls post-hoc test, as indicated. 
Statistical analyses were performed using SPSS for Windows 
v.8.0 (SPSS Inc., Chicago, IL). The results are reported as 
mean, 95% upper and lower confidence limits (95% CI), and 
standard error of mean or standard deviation, with p-values 
< 0.05 considered statistically significant.
RESULTS
Table 1 summarizes demographic and surgical data. Age, 
height, weight, body mass index, duration of surgery and 
time from the end of surgery to propofol infusion suspension 
were similar in both groups. The mean length of CPB in the 
CABG group was 79 ± 23 minutes. After discontinuation 
of propofol infusion, the times to awakening and tracheal 
extubation were significantly greater in the CABG group. 
Dobutamine infusion in doses up to 5.0 µg.kg-1.min1 
was required in two patients during weaning from CPB; 
nitroglycerine was administered to five patients and sodium 
nitroprusside to four patients after CPB. In the OPCAB 
group, three patients received norepinephrine infusion with 
doses ranging between 0.01-0.2 µg.kg-1 during cardiac 
tilt. All patients achieved hemodynamic stability in the 
immediate postoperative period and all vasoactive drugs were 
discontinued within 24 hours after surgery. The cumulative 
consumption of morphine in the first 12 hr after the end of 
the propofol infusion was 7.2 ± 6.6 mg in the CABG group 
and 10.6 ± 8.8 mg in the OPCAB group (p=0.36).
A total of 520 blood samples were analyzed for plasma 
propofol concentration in the CABG (290 samples) and 
OPCAB (230 samples) groups. The groups did not differ 
with respect to total propofol doses infused during surgery 
(1452 ± 256 mg vs. 1408 ± 289 mg in the CABG and 
OPCAB groups, respectively, p=0.648), or with respect to 
the total propofol doses infused from the end of surgery to 
the time of tracheal extubation (144 ± 81 mg vs. 95 ± 68 mg 
in the CABG and OPCAB groups, respectively, p=0.26). The 
actual plasma propofol concentrations in CABG and OPCAB 
groups over time are displayed in figure 1. Plasma propofol 218
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concentrations did not differ between the groups throughout 
the study, except during the moments corresponding to 
cardiopulmonary bypass in the CPB group, during which 
the plasma concentration was higher in the OPCAB group. 
When the propofol PK parameters were analyzed for time 
points after CPB up to the time of observation in the CPB 
group and for corresponding time points in the OPCAB 
group, we observed that the fast elimination rate constant 
in the CPB group was double that of the OPCAB group 
(p <0.01), while the biological half-life was 50% lower 
(p <0.01) (Table 2). Patients undergoing CPB exhibited a 
higher terminal elimination half-life (p <0.01) and higher 
total plasma clearance (p <0.01) when compared to patients 
in the OPCAB group. Figure 2 shows plasma propofol 
concentration measures plotted against respective Bispectral 
Index values after the end of coronary grafting until the end 
of blood sampling in both groups.
During the postoperative period, BIS values were 
significantly higher in the OPCAB group in comparison to 
the CABG group, as shown in figure 3. PK-PD modeling 
performed by plotting the BIS values as a function of the 
plasma concentrations demonstrated hysteresis between the 
CABG and OPCAB group curves, as shown in figure 4. For 
the same plasma propofol concentrations in the wakening 
period, higher values of BIS are observed in the OPCAB 
group. Table 3 displays the results of the sigmoid EMAX model 
applied to both groups, with r2= 0.95 in the OPCAB group 
and r2= 0.96 in the CABG group. 
DISCUSSION
When combined with potent opioid analgesics, propofol 
infusion provides excellent hemodynamic stability during 
cardiac surgery and allows for early tracheal extubation 
in the immediate postoperative period.2,9,16 The use of 
CPB to maintain adequate circulation and tissue perfusion 
Table 1 - Demographic, surgical and postoperative data of the patients in both the CABG and OPCAB treatment groups
CABG OPCAB p value
Gender (male:female) 09:01 07:03 0.26
Age (years) 62 ± 8 68 ± 7 0.07
Body weight (kg) 75 ± 11 75 ± 8 0.93
Height (m) 1.63 ± 0.04 1.66 ± 0.10 0.55
Body mass index 28 ± 5 27 ± 3 0.74
Length of surgery (min) 278 ± 54 287 ± 77 0.75
Time from the end of surgery to end of propofol infusion (min)  91 ± 36 64 ± 31 0.10
Time from the end of propofol infusion to awakening and tracheal extubation (min) 334 ± 117 216 ± 85 0.04
CABG – on-pump coronary artery bypass graft surgery; OPCAB – off-pump coronary artery bypass graft surgery. Data reported as mean ± standard 
deviation.
Figure 1 - Plasma propofol concentrations as a function of time after the 
induction of anesthesia. Closed circles represent the coronary artery bypass 
graft (CABG) group and open circles represent the off-pump coronary 
artery bypass (OPCAB) group. Data reported as mean values ± standard 
error * p ≤ 0.05
Table 2 - Pharmacokinetic variables for patients undergoing 
CABG and OPCAB procedures
Parameter CABG OPCAB p value
a (hour-1) 4.14 ± 1.53 4.76 ± 2.96 0.58
T1/2 a (hour) 0.19 ± 0.07 0.21 ± 0177 0.15 0.71
b (hour-1) 0.40 ± 0.10 0.21 ± 0.06 <0.01
T1/2 a (hour) 1.82 ± 0.5 3.67 ± 1.15 <0.01
g (hour-1) 0.11 ± 0.02 0.07 ± 0.01 <0.01
T1/2 g (hour) 6.27 ± 1.29 10.5 ± 2.18 <0.01
CLT (mL min-1 kg-1) 28.36 ± 11.40 18.29 ± 7.67 0.03
Vdb (L kg-1) 4.39 ± 1.90 5.61 ± 2.69 0.26
Vdg (L kg-1) 15.99 ± 9.40 16.74 ± 8.69 0.86
α = distribution rate hybrid constant, T1/2 α = Distribution half-life; β = fast 
elimination rate constant; T1/2 β = biological half-life; γ = slow elimination 
rate constant; T1/2 γ = terminal elimination half-life; CLT = total plasma clear-
ance; Vd β = volume of distribution beta; Vd γ = volume of distribution 
gamma. Data are expressed as mean values ± SD.219
CLINICS 2009;64(3):215-21 Propofol pharmacokinetics and dynamics after CPB
Barbosa RAG et al.
during coronary graft, on the other hand, is known to alter 
the pharmacokinetics and pharmacodynamics of several 
anesthetic drugs, thus increasing their central nervous system 
depressant effects.4,17 Although the alterations induced by 
CPB on propofol pharmacokinetics are well documented, 
no studies have compared these effects of CPB on propofol 
pharmacokinetics to a control group undergoing the same 
procedure without CPB in the context of impact on arousal 
and time to extubation. 
In this study, we observed that plasma propofol 
concentrations were similar in both groups throughout the 
surgery and recovery period when the same infusion regimen 
was applied by means of TCI, except during coronary 
grafting, when significantly lower concentrations were 
measured in the CABG group. After the end of CPB, despite 
similar plasma propofol concentrations, BIS values remained 
lower in the CABG group and time to extubation was greater 
after the interruption of propofol infusion . Nonetheless, 
the total amount of infused propofol was equivalent in both 
groups (1408 ± 289 mg versus 1452 ± 256 mg); the PK-PD 
modeling demonstrated comparable maximal BIS effects 
(EMAX) in the OPCAB and CABG groups (30.4 versus 38.0); 
and the EC50 was reduced by 33% in patients undergoing 
Figure 2 - Plasma propofol concentration measures plotted against respec-
tive bispectral index values after the end of coronary grafting up to the end 
of blood sampling. Closed circles represent the coronary artery bypass graft 
(CABG) group and open circles represent the off-pump coronary artery 
bypass (OPCAB) group
Figure 3 - Time course of changes in bispectral index (BIS) values. Closed 
circles represent coronary artery bypass graft (CABG) group and open 
circles represent off-pump coronary artery bypass (OPCAB) group. After 
discontinuation of the propofol infusion, time “0” represents the point at 
which the BIS values were higher in the OPCAB group as compared to the 
CABG group. Data reported as mean ± standard error * p < 0.01
Figure 4: Pharmacokinetic-pharmacodynamic modeling using sigmoid EMAX 
model of plasma propofol concentration and bispectral index (BIS) values 
during and after surgery
Table 3 - Pharmacokinetic-pharmacodynamic modeling using 
bispectral index (BIS) values and plasma propofol concentra-
tions in the CABG and OPCAB treatment groups
Sigmidal EMAX model
CABG
(Mean (95% CI)
OPCAB
(Mean (95% CI)
Best-fit values
  Emax (minimum BIS value) 30.4 (20.0 to 40.8) 38.0 (32.1 to 43.9)
  Baseline (BIS) 93 (86 to 100) 92 (86 to 97)
  Hillslope 1.4 (0.8 to 2.1) 3.6 (1.6 to 5.6)
  EC50 (mg L-1) 06 (0.4 to 0.8) 0.9 (0.8 to 1.0)
Goodness of fit
  R2 0.96 0.95
Emax: concentration of drug required to produce maximum effect; EC50: 
concentration of drug required to produce 50% of maximum effect; . CABG 
– coronary artery bypass graft surgery; OPCAB – off-pump coronary artery 
bypass graft surgery220
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CPB when compared to patients submitted to off-pump 
surgery. Taken together, these findings suggest an enhanced 
sensitivity to propofol in patients undergoing CPB. This 
hypothesis is supported by published studies that reported 
similar results in patients receiving propofol during and after 
CPB. Yoshitani et al. reported that, during normothermic 
CPB, the burst suppression rate gradually increased in 
response to three fixed dose regimens of 4, 5 and 6 mg.kg-
1.h-1 during CPB compared to baseline18. Takizawa et al. 
reported that the anesthetic effect of propofol increased 
significantly during CPB without any alteration in the total 
drug concentration.5 This mechanism has already been 
validated for volatile anesthetics in experimental models19,20 
and clinical contexts,6,17 where the minimum alveolar 
concentration (MAC) was decreased after CPB.
Upon first glance, these findings could be entirely 
attributed to the increased sensitivity of the brain to propofol 
after CPB. Nevertheless, the pharmacokinetics of propofol 
were significantly modified by CPB, and this alteration could 
contribute to the increased central nervous system depressant 
effects observed in the CABG group postoperatively. 
Propofol elimination was found to be biphasic; the fast 
elimination and slow elimination rate constants were higher 
in the CABG group than in the OPCAB group, while fast and 
slow elimination half-life values were lower. Furthermore, 
total propofol plasma clearance was significantly higher 
in the CPB group. These alterations in pharmacokinetics 
suggest that there is an increase in the unbound fraction of 
propofol in blood after CPB and that more drug is available 
for clearance from the circulation during a given unit of time. 
If the binding of propofol to plasma proteins is reduced, the 
availability of free drug at the site of action is also greater, 
contributing to the more intense central nervous system 
depressant effect observed in the CABG group. 
In fact, it is known that CPB may lead to a reduction 
in the amount of plasma protein that binds to several 
drugs, including propofol. Our findings support those 
reported by Hiraoka et al., who observed that the fraction 
of unbound propofol in blood increased by two-fold during 
cardiopulmonary bypass.8 The same group also reported 
that the total concentration of propofol in blood using 
doses of either 4 or 6 mg.kg-1.h-1 remained unchanged after 
the initiation of CPB, when compared to pre-CPB plasma 
concentration values in both groups; however, the fraction of 
unbound propofol in blood doubled during CPB.5 Dawson et 
al also reported that CPB caused a reduction in total propofol 
plasma concentrations, while unbound concentrations 
remained stable.21 Unfortunately, we did not measure the 
fraction of circulating unbound plasma propofol. However, 
based on the indirect pharmacokinetic data found in this 
study and on the strength of the evidence from the literature, 
we maintain that CPB-induced alterations in propofol 
pharmacokinetics play a significant role in its increased post-
CPB hypnotic effects.
It could be argued that the concomitant use of sufentanil 
may confound the BIS evaluation in the CABG group, despite 
the fact that the infusion rate was the same for both groups 
throughout the operation. Lysakowki et al. studied the effects 
of opioids on loss of consciousness and BIS values during 
propofol induction of anesthesia and concluded that sufentanil 
produced minimal electrophysiological alterations in the 
central nervous system.22 In addition, Hudson et al. reported 
that CPB had clinically insignificant effects on sufentanil 
kinetics in adults.23 According to these studies, we can exclude 
any significant effect of CPB on sufentanil PK. The association 
of the two mechanisms may explain the differences between 
the groups in terms of the propofol pharmacodynamics: a) 
increased brain sensitivity to propofol and b) extensively 
altered post-CPB propofol pharmacokinetics, leading to an 
increase in unbound propofol in blood plasma.
This study has some limitations. The propofol infusion 
device DiprifusorR (Astra-Zeneca, Detroit, USA) used in 
the study is based on Marsh’s pharmacokinetic model,13 
which does not take into account intraoperative physiologic 
alterations, such as hemodilution and hypothermia, or 
changes in drug-protein binding. Despite the well-known 
limitations of propofol administration using this model,24 
it has been successfully used in cardiac surgery.2 Since 
measured plasma propofol concentrations were used in PK-
PD analysis instead of the plasma concentrations predicted 
from Marsh’s model (as in the great majority of studies), 
and given that the plasma concentrations were very similar 
in both groups after CPB, we can assume that the use of 
DiprifusorR did not interfere with the results of the study.
Another limitation of this study is the fact that the 
surgical approach was defined on the day of the surgery by 
the senior surgeon based on the anatomical characteristics 
of the coronary arteries. In some cases, the decision was 
changed intraoperatively. This method prohibited use of 
a random preordered group assignment. However, since 
all patients were operated upon by a single surgical team 
and possessed similar demographic and physiologic 
characteristics, this selection bias is likely minimal.
In conclusion, despite the increased brain sensitivity 
to propofol after CPB, the difference in hypnotic effects 
after CPB when compared to an adequate control group 
undergoing the same surgery without CPB results from 
changes in its pharmacokinetics. 
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